Can Binimetinib treat kras mutations?

Binimetinib (Binimetinib) combined with (erlotinib) demonstrated manageable safety and modest efficacy, including a confirmed objective response, in one patient with a KRAS mutation. Although the clinical utility of this particular combination is limited, these results support the development of combinations using novel small molecule RAS inhibitors, selective EGFR, and other MAPK pathway inhibitors, many of which have improved therapeutic indices. The clinical guidelines for bimetinib do not allow the treatment of diseases associated with Kras mutations.

Activating mutations of EGFR or KRAS are very common in non-small cell lung cancer and share activation of the MAPK pathway, which may be suitable for combination therapy to prevent negative feedback activation. In a phase 1/1B trial, the combination of bimetinib and erlotinib was tested in patients with advanced non-small cell lung cancer who had received at least one prior therapy (unless they had an activatingEGFR mutation, which may be treatment naïve). Results showed that common side effects across all doses included diarrhea(69.8%), rash (44.2%), fatigue (32.6%) and nausea (32.6%), mainly grade 1/2. Among patients with KRAS mutations, 1 (5%) had confirmed partial response and 8 (36%) had stable disease as best overall response. Among patients with EGFR mutations, 8 (89%) had partial responses, 8 were TKI pretreated and had no partial responses, and 1 (13%) had stable disease, which was the best overall response.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.